⚠ Data freshness notice: the most recent refresh of NHTSA was incomplete, so a
very recent recall may be missing. Everything shown is accurate as of the last checked time on this page —
for anything time-critical, confirm with the official sources linked below.
FDAClass II · Drug · Recalled May 6, 2026
fentaNYL Citrate Injectable Solution recall — Wells Pharma of Houston LLC
Hazard: cGMP deviations.
Class II: may cause temporary or medically reversible health consequences.
View the official FDA enforcement record (openFDA) ↗
- Official recall ID
- D-0505-2026
- Brand
- Wells Pharma of Houston
- Classification
- Class II
- Units affected
- 50 syringes
- Recall status
- Ongoing
- Initiated
- Voluntary: Firm initiated
Description
fentaNYL Citrate Injectable Solution, Narcotic, CII, 1250 mcg/25mL (50 mcg per mL), 25 mL, wells pharma of Houston, NDC 73702-204-25.
Affected products
Companies & origin
- Recalling firm location
- Houston, TX, United States
- Firm address
- 9265 Kirby Dr, 77054-2520
Identifying details (verbatim from the notice)
- Product codes / lots
- Lot 011226204250063, Exp Date 05/14/2026
- Distribution
- U.S. Nationwide.
- Firm notified the public via
- Letter
- FDA event ID
- 98694
- Recall initiated
- April 1, 2026
- FDA classified
- April 28, 2026
- FDA report date
- May 6, 2026
Source: U.S. Food & Drug Administration. This page mirrors the official public-domain record verbatim;
the linked government source is authoritative. Source last checked July 23, 2026 at 11:04 PM UTC.
Report a data error on this page